Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

1. Tuberculosis among First Nations, Inuit and Métis children and youth in Canada: Beyond medical management

Tuberculosis among First Nations, Inuit and Métis children and youth in Canada: Beyond medical management First Nations, Inuit and Métis people in Canada continue to be disproportionately affected by tuberculosis (TB), a disparity rooted primarily in factors such as poverty, crowded and inadequate housing, food insecurity, and inequitable health care access. Historical TB control practices in Canada have contributed to stigma and discrimination toward those with the disease, as well (...) , improve the quality and uptake of services for treatment and prevention in families and communities at risk. They can also advocate for sustainable, community-driven TB elimination strategies that incorporate First Nations, Inuit and Métis principles of wellness, healing and self-determination.   Key words: First Nations, Inuit, Métis, Indigenous, child health, tuberculosis, LTBI, social determinants

2020 Canadian Paediatric Society

2. Tuberculosis and pregnant women

Tuberculosis and pregnant women Tuberculosis and pregnant women - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis and pregnant women Guidance for patients and the public and for clinical staff involved in treating pregnant women. Published 1 November 2013 Last (...) . Please tell us what format you need. It will help us if you say what assistive technology you use. Details One set of guidance is for pregnant women and members of the public. The other is for clinical staff treating pregnant women who have had contact with a person with infectious tuberculosis ( 17 December 2019 Updated to reflect changes in national guidance and availability of services. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you

2020 Public Health England

3. Tuberculosis: information for prison and immigration removal centre staff

Tuberculosis: information for prison and immigration removal centre staff Tuberculosis: information for prison and immigration removal centre staff - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis: information for prison and immigration removal centre staff Advice (...) information for prison and immigration removal centre staff on: spotting symptoms of 17 December 2019 Updated 'Tuberculosis: information for prisons and immigration removal centre staff'. 22 March 2019 Updated guidance on 'Tuberculosis (TB): information for discipline and wing staff'. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National

2020 Public Health England

4. Tuberculosis (TB) and homelessness

Tuberculosis (TB) and homelessness Tuberculosis (TB) and homelessness - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis (TB) and homelessness Advice for people who work in the homeless sector. Published 1 November 2013 Last updated 16 December 2019 — From: Documents (...) . It will help us if you say what assistive technology you use. Details People who work in the homelessness sector can use this information to help them to recognise 16 December 2019 Updated documents. 7 January 2016 Added 'Tuberculosis (TB) and homelessness: information for homelessness service managers'. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like

2020 Public Health England

5. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Full Text available with Trip Pro

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Respir Crit Care Med Actions , 200 (10), e93-e142 2019 Nov 15 Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , PMID: 31729908 PMCID: DOI: Item in Clipboard Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA

2020 EvidenceUpdates

6. Tuberculosis (TB) and children

Tuberculosis (TB) and children Tuberculosis (TB) and children - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Tuberculosis (TB) and children Guidance for all of those who work with children. Explains how (...) Updated 'Tuberculosis and children: information for all of those who work with children'. 1 November 2013 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National Insurance number or credit card details. What were you doing? What went wrong? Send Help us improve GOV.UK To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you

2019 Public Health England

7. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. Full Text available with Trip Pro

Community-wide Screening for Tuberculosis in a High-Prevalence Setting. The World Health Organization has set ambitious targets for the global elimination of tuberculosis. However, these targets will not be achieved at the current rate of progress.We performed a cluster-randomized, controlled trial in Ca Mau Province, Vietnam, to evaluate the effectiveness of active community-wide screening, as compared with standard passive case detection alone, for reducing the prevalence of tuberculosis (...) . Persons 15 years of age or older who resided in 60 intervention clusters (subcommunes) were screened for pulmonary tuberculosis, regardless of symptoms, annually for 3 years, beginning in 2014, by means of rapid nucleic acid amplification testing of spontaneously expectorated sputum samples. Active screening was not performed in the 60 control clusters in the first 3 years. The primary outcome, measured in the fourth year, was the prevalence of microbiologically confirmed pulmonary tuberculosis among

2019 NEJM

8. Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines

Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Diagnosis of Tuberculosis: Clinical Effectiveness and Guidelines Last updated: July 2, 2019 Project Number: RA1044-000 Product Line: Research Type: Devices and Systems Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of interventions used for the diagnosis of tuberculosis? What are the evidence-based guidelines regarding the diagnosis of tuberculosis? Key Message One health technology assessment and fourteen systematic reviews (twelve with meta-analysis) were identified regarding the clinical effectiveness of interventions used to diagnose tuberculosis. In addition, seven evidence-based guidelines were identified regarding

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines

Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines Interventions for the Treatment or Management of Tuberculosis: Clinical Effectiveness and Guidelines Last updated: July 8, 2019 Project Number: RA1045-000 (...) Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of interventions used to treat or manage individuals with tuberculosis? What are the evidence-based guidelines regarding the treatment or management of individuals with tuberculosis? Key Message Nine systematic reviews (eight with meta-analysis) and four evidence-based guidelines were identified regarding the treatment or management of individuals

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines

Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Last updated: June 24, 2019 Project Number: RA1043-000 Product Line: Research Type: Devices and Systems Report Type (...) : Reference List Result type: Report Question What is the clinical effectiveness of interventions used to screen individuals for tuberculosis? What are the evidence-based guidelines regarding the screening of individuals for tuberculosis? Key Message Twelve systematic reviews (eight with meta-analysis) were identified regarding the clinical effectivenessof interventions used to screen individuals for tuberculosis. In addition, four evidence-based guidelines were identified regarding the screening

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Pretomanid - For treatment-resistant forms of tuberculosis

Pretomanid - For treatment-resistant forms of tuberculosis Drug Approval Package: Pretomanid U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Pretomanid Company: The Global Alliance for TB Drug Development, Inc. (TB Alliance) Application Number: 212862 Approval Date: 08/14/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2019 FDA - Drug Approval Package

12. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. (Abstract)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Accurate diagnosis of tuberculosis in people living with HIV is difficult. HIV-positive individuals have higher rates of extrapulmonary tuberculosis and the diagnosis of tuberculosis is often limited to imaging results. Ultrasound is such an imaging test that is widely used as a diagnostic tool (including point-of-care) in people suspected of having (...) abdominal tuberculosis or disseminated tuberculosis with abdominal involvement.To determine the diagnostic accuracy of abdominal ultrasound for detecting abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals.To investigate potential sources of heterogeneity in test accuracy, including clinical setting, ultrasound training level, and type of reference standard.We searched for publications in any language up to 4 April 2019 in the following databases

2019 Cochrane

13. Management of drug-resistant tuberculosis. (Abstract)

Management of drug-resistant tuberculosis. Drug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase. Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan (...) , Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%. Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable outcomes than those treated for drug-susceptible tuberculosis. Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing

2019 Lancet

14. Challenges and controversies in childhood tuberculosis. (Abstract)

Challenges and controversies in childhood tuberculosis. Children bear a substantial burden of suffering when it comes to tuberculosis. Ironically, they are often left out of the scientific and public health advances that have led to important improvements in tuberculosis diagnosis, treatment, and prevention over the past decade. This Series paper describes some of the challenges and controversies in paediatric tuberculosis, including the epidemiology and treatment of tuberculosis in children (...) . Two areas in which substantial challenges and controversies exist (ie, diagnosis and prevention) are explored in more detail. This Series paper also offers possible solutions for including children in all efforts to end tuberculosis, with a focus on ensuring that the proper financial and human resources are in place to best serve children exposed to, infected with, and sick from all forms of tuberculosis.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 Lancet

15. Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations. (Abstract)

Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations. Tuberculosis is an infectious bacterial disease that is spread via respiratory droplets from infected individuals to susceptible contacts. To eliminate this disease from low- and medium-incidence settings, people who are most likely to be infected (contacts) must be identified. Recently, study authors have examined alternate approaches to contact

2019 Cochrane

16. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Full Text available with Trip Pro

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the newest version, are the only World Health Organization (WHO)-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in persons with signs and symptoms of tuberculosis, at lower health system levels. A previous Cochrane Review found Xpert MTB/RIF sensitive and specific for tuberculosis (...) (Steingart 2014). Since the previous review, new studies have been published. We performed a review update for an upcoming WHO policy review.To determine diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculosis in adults with presumptive pulmonary tuberculosis (PTB) and for rifampicin resistance in adults with presumptive rifampicin-resistant tuberculosis.We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin

2019 Cochrane

17. Tuberculosis (TB): information for discipline and wing staff

Tuberculosis (TB): information for discipline and wing staff Tuberculosis (TB): Information for discipline and wing staff 2019 Tuberculosis (TB) is an airborne infectious disease that spreads through prolonged contact. TB rates in the UK are on the increase and vulnerable groups, such as people who are in prisons may be at risk. Not all individuals with TB can infect others, only TB affecting the lungs is infectious. Late diagnosis, inadequate treatment, overcrowding, poor ventilation (...) and repeated prison transfers of infectious individuals encourages the spread of TB infection. The prison healthcare staff and your local CCDC are there to support and inform you. Think TB! There are many causes of a persistent cough, the most common of which include viral infection and smoking. A persistent cough can also be a sign of drug misuse (or coming off drugs), tuberculosis or other serious health problems. If an individual in your care has a cough which seems to get worse over a period lasting

2019 Public Health England

18. MVA85A vaccine to enhance BCG for preventing tuberculosis. Full Text available with Trip Pro

MVA85A vaccine to enhance BCG for preventing tuberculosis. Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vaccine produced to prevent tuberculosis.To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.We searched the Cochrane Infectious Diseases Group (...) Specialized Register; Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (Ovid); and four other databases. We searched the WHO ICTRP and ClinicalTrials.gov. All searches were run up to 10 May 2018.We evaluated randomized controlled trials of MVA85A vaccine given with BCG in people regardless of age or HIV status.Two review authors independently assessed the eligibility and risk of bias of trials, and extracted and analyzed data. The primary outcome was active tuberculosis disease

2019 Cochrane

19. Tuberculosis. (Abstract)

Tuberculosis. Tuberculosis remains the leading cause of death from an infectious disease among adults worldwide, with more than 10 million people becoming newly sick from tuberculosis each year. Advances in diagnosis, including the use of rapid molecular testing and whole-genome sequencing in both sputum and non-sputum samples, could change this situation. Although little has changed in the treatment of drug-susceptible tuberculosis, data on increased efficacy with new and repurposed drugs have (...) led WHO to recommend all-oral therapy for drug-resistant tuberculosis for the first time ever in 2018. Studies have shown that shorter latent tuberculosis prevention regimens containing rifampicin or rifapentine are as effective as longer, isoniazid-based regimens, and there is a promising vaccine candidate to prevent the progression of infection to the disease. But new tools alone are not sufficient. Advances must be made in providing high-quality, people-centred care for tuberculosis. Renewed

2019 Lancet

20. Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV Full Text available with Trip Pro

Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV The recommended tuberculosis (TB) intensified case finding (ICF) algorithm for people living with HIV (symptom-based screening followed by Xpert MTB/RIF [Xpert] testing) is insufficiently sensitive and results in unnecessary Xpert testing.To evaluate whether novel ICF algorithms combining C-reactive protein (CRP)-based screening with urine Determine TB-LAM (TB-LAM), sputum Xpert

2019 EvidenceUpdates